



PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) Sheet 1 of 2	Application Number	09/821,244
	Filing Date	March 29, 2001
	First Named Inventor	J.G. Breitenbucher et al.
	Group Art Unit	1625
	Examiner Name	B.I. Dentz
	Attorney Docket Number	ORT-1395

U.S. PATENT DOCUMENTS						
Examiner Initials	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear
		Number	Kind Code ² (if known)			
B.D.		4,727,145	A	Press	02-1988	
		4,833,149	A	Press	05-1989	
		4,861,897	A	Press et al.	08-1989	
		5,182,291	A	Gubin et al.	01-1993	
		5,352,707	A	Pompni et al.	10-1994	
		5,385,912	A	Neuenschwander et al.	01-1995	
B.D.		5,681,954	A	Yamamoto et al.	10-1997	

FOREIGN PATENT DOCUMENTS								
Examiner Initials	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear	T ³
		Office ³	Number ⁴	KindCode ⁵				
B.D. ↓		EP	0 289 371	A1	Synthelabo	11-1988		
		EP	0 978 512	A1	Societe Civile Bioprojet	02-2000		
		JP	52 113992	A1	Janssen Pharmaceutica N.V.	08-1997		
		WO	97/43271	A1	Warner-Lambert Company	11-1997		
		WO	98/06703	A1	Eli Lilly and Company	11-1998		
		WO	98/48797	A1	Eli Lilly and Company	11-1998		
		WO	99/32115	A1	Advanced Research and Technology Institute, Inc. et al.	07-1999		
		WO	99/33822	A1	SmithK-Line Beecham Laboratories Pharmaceutiques et al.	07-1999		
B.D.		WO	01/10050	A1	Rohde & Schwarz GmbH & Co. KG	01-2002		
		WO	01/74815	A2	Ortho McNeil Pharmaceutical, Inc.	10-2001		

Examiner Signature	<i>B. Dentz</i>	Date Considered	2-9-2004
-----------------------	-----------------	--------------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450



PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) Sheet 2 of 2	Application Number	09/821,244
	Filing Date	March 29, 2001
	First Named Inventor	J.G. Breitenbucher et al.
	Group Art Unit	1625
	Examiner Name	B.I. Dentz
	Attorney Docket Number	ORT-1395

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
BD		AGARWAL, Shiv K. et al., "Synthesis and pharmacological activities of 1-(2,4-disubstituted phenoxy)-3-[N1-N4-arylpiperazinyl]propanes and 1-(4-chlorobenzoyl)-3-substituted 6-methoxy-2- α -[3-N1-(N4-phenylpiperazinyl)propoxy]phenylindoles", Indian J. Chem., Sect. B (1991), 30B(4), 413-16	
		JOSHI, Krishna C. et al., "Preparation of new fluorine containing 2-phenylindole derivatives as antifertility agents", J. Indian Chem. Soc. (1985), 62(5), 388-90	
		TAKEUCHI, K. et al., "1,2-disubstituted indole, azaindole and benzimidazole derivatives possessign amine moiety: a novel series of thrombin inhibitors" Bloorg. Med. Chem. Lett. (2000), 10(20), 2347-2351	
		WALCZYNSKI, Krzysztof et al., "Non-imidazole histamine H3 ligands, part 2: New 2-substituted benzothiazoles as histamine H3 antagonists", Archiv de Pharmazie, Vol. 332, No. 11, November 1999, pp. 389-398	
BD		WALCZYNSKI, Krzysztof et al., "Non-imidazole histamine H3 ligands. Part I. Synthesis of 2-(1-Piperazinyl)- and 2-(hexahydro-1H, 4-diazepin-1-yl) benzothiazole derivatives as H3-antagonists with H1 blocking activities", Biosciences Information Services, Farmco, Vol. 54, No. 10, October 30, 1999, pp. 684-694	

Examiner Signature	<i>B. I. Dentz</i>	Date Considered	2-9-2004
--------------------	--------------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.